Nestlé India Q4 Results: Strong double-digit growth in beverages and confectionery; domestic sales highest ever in a quarter, says management
By Aditya Bhagchandani Published on April 24, 2025, 12:05 IST
Nestlé India on Thursday announced its financial results for the fourth quarter and financial year ended March 31, 2025, reporting solid performance across several key segments including beverages, confectionery, and out-of-home consumption. The Board of Directors approved both standalone and consolidated results and declared a final dividend of ₹10 per equity share. Robust quarterly performance
Commenting on the results, Suresh Narayanan, Chairman and Managing Director of Nestlé India, said the company saw strong double-digit growth in Beverages and Confectionery, with three out of four product groups showing healthy momentum. Domestic sales crossed ₹5,235 crore, marking the highest ever in a quarter, led by improving volume growth and resilient demand. Category-wise highlights Powdered and Liquid Beverages emerged as the biggest contributor, with high double-digit growth . NESCAFÉ continued to gain market share, adding 5.1 million new households to the coffee category. NESCAFÉ's Ready-to-Drink cold coffee also expanded in India.
Confectionery recorded high single-digit growth , led by the strong performance of KITKAT , making India the second-largest market for the brand globally.
Prepared Dishes and Cooking Aids , led by MAGGI , returned to volume growth. MAGGI Masala-Ae-Magic also maintained consistent growth, with India remaining its largest market worldwide.
Milk Products and Nutrition saw innovation-led gains, including the launch of CERELAC and CEREGROW variants with no refined sugar .
Petcare , now fully integrated into Nestlé India, posted its highest ever growth , driven by PURINA brands like FELIX, FRISKIES, and PRO PLAN.
The Out-of-Home (OOH) business also surged, now including KITKAT Professional Spread, aimed at chefs and commercial kitchens. Strategic expansions and sustainability
Nestlé India also opened its first NESPRESSO boutique in New Delhi, receiving an enthusiastic response from coffee enthusiasts. Meanwhile, the company's Quick Commerce channel grew significantly, contributing 8.5% of total domestic sales in FY25.
The company expanded its RUrban strategy, reaching nearly 208,500 villages and boosting rural touchpoints to 27,730. Investments continued across infrastructure and innovation, including the upcoming Odisha factory with a first-phase outlay of ₹900 crore, part of its ₹6,500 crore investment plan from 2020 to 2025. Sustainability and social impact
Nestlé India underlined its commitment to environmental sustainability through initiatives like its Zer'Eau technology, which recycles water extracted from milk to reduce groundwater use by 20%. Other sustainability goals included increasing renewable energy reliance, regenerative agriculture, and circular packaging.
The company claimed to have positively impacted over 16 million lives through efforts aligned with UN Sustainable Development Goals, ranging from nutrition and education to sanitation and rural development. Dividend declaration
The Board has recommended a final dividend of ₹10 per share for FY25. The record date for the dividend has been fixed as July 4, 2025.
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules
OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market RulesNantes, June 20th, 2025, 7:30 p.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), publishes a 'Questions and Answers' document for all its shareholders and informs the market of ongoing procedures, in line with its commitment to holding the annual General Meeting with transparency, serene debates, and compliance with market rules. In line with its continuous information and transparency approach towards shareholders, the Company has published a "Questions and Answers" document, accessible at the following address: intended to answer the main questions of shareholders regarding recent events. Nicolas Poirier, CEO of OSE, states: "We have a responsibility to all those who expect seriousness and results from OSE, primarily the patients. We cannot leave the false information communicated to the market unanswered. For example, there is no plan to use venture debt instruments. In response to these unfounded rumors, we have decided to publish this "Questions and Answers" document. An exchange with all shareholders will be organized soon in the same spirit." Following the declaration of a concerted action and the submission of several resolutions aimed at significantly altering the composition of the Board of Directors by a group of shareholders1, the Company reminds the market, that it had requested and obtained, by order of the President of the Nantes Commercial Court dated June 10, 2025, the postponement of the General Meeting initially scheduled for June 25, 20252. The "group of shareholders" notified the Company today of their challenge to this decision, through a request for the retraction of the June 10, 2025 order, with a hearing scheduled for Tuesday, June 24, 2025. The postponement of the General Meeting to a later date, aims to address the concerns expressed by certain shareholders in this tense context and to ensure that the consultation of its shareholders can take place in a serene democratic framework, ensuring complete and fair information. This general meeting cannot be a stage for attempts to destabilize and spread erroneous information about the Company. In this regard, OSE Immunotherapeutics has filed a request today with the Nantes Commercial Court, within the framework of an accelerated procedure (known as "fixed date"), for an action against this same group of shareholders. This action concerns the regularity of the declaration of the concerted action, with the aim of ensuring compliance with the principles of transparency governing shareholder democracy ahead of the Company's next General Meeting. Subject to the evolution of legal proceedings, the Company currently plans to hold the General Meeting on September 30, 2025. In this context, the Board of Directors reaffirms its commitment in favor of a transparent, responsible and constructive dialogue among all stakeholders. This commitment is reflected in the procedures and actions undertaken by the Company but also by the joint mobilization of the management and the Board of Directors to install a dialogue with the "group of shareholders". A constructive and formal framework for exchange has thus been proposed to move forward together in the interest of the Company and all its shareholders. ABOUT OSE IMMUNOTHERAPEUTICS OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on information about OSE Immunotherapeutics assets is available on the Company's website: Follow us on Fiona Dé French Media Contact FP2COMFlorence Portejoiefportejoie@ 6 07 768 283 U.S. Media ContactRooney Partners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. 1 Press release of June 9, 20252 Press release of June 11, 2025 Attachment EN_250620_FINALSign in to access your portfolio
Business Upturn
7 hours ago
- Business Upturn
Aarvi Encon secures twin manpower contracts worth over Rs 30 crore
By Aditya Bhagchandani Published on June 20, 2025, 16:40 IST Aarvi Encon Limited has announced the receipt of two significant work orders from a leading multinational EPC company, with a combined value exceeding Rs 30.67 crore. As per the company's regulatory filings, the first contract is worth Rs 22.53 crore and entails supplying manpower on an outsourcing basis to various project sites and offices across India. This contract is valid for two years starting June 3, 2025, and will continue until June 4, 2027. In addition to this, Aarvi Encon has secured a second contract valued at Rs 8.13 crore. This one-year agreement, effective from July 1, 2025, involves similar manpower supply services at multiple domestic locations. Both contracts are with the same unnamed domestic entity and fall under non-related party transactions. The company has signed a Non-Disclosure Agreement, and therefore, the client's identity remains confidential. These orders bolster Aarvi Encon's pipeline and reaffirm its positioning in India's engineering staffing and outsourcing segment. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
8 hours ago
- Business Upturn
Granules India's Bonthapally facility completes US FDA inspection with one observation
By Aditya Bhagchandani Published on June 20, 2025, 16:28 IST Granules India announced on June 20, 2025, that its API Unit-I facility at Bonthapally, located in Sangareddy District near Hyderabad, has successfully completed a US FDA inspection conducted between June 16 and June 20. The inspection concluded with a single Form 483 observation. In an exchange filing, the company stated it would address the observation within the prescribed timeline. Granules emphasized that the Bonthapally facility is one of the world's largest single-site Paracetamol API manufacturing units by volume and also houses manufacturing plants for Metformin and Guaifenesin APIs. The company assured investors that the outcome will be managed in line with regulatory expectations. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
